Patrick G. Clay

Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data

Kathy K. Byrd, John Hou, Ron Hazen et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 267 citations · Full text

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2018 · 140 citations

Treatment And Prevention, Antiviral Drug Development, Clinical Trials +7

DISCOVERY OF MUTATED SUBNETWORKS ASSOCIATED WITH CLINICAL DATA IN CANCER

Fabio Vandin, Patrick G. Clay, Eli Upfal et al. · 2011 · 113 citations

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Jean‐Michel Molina, Kathleen Squires, Paul E. Sax et al. · The Lancet HIV · 2019 · 92 citations

Treatment And Prevention, Antiretroviral-naive Adults, Clinical Trials +6

The Essential Research Curriculum for Doctor of Pharmacy Degree Programs

Mary W. Lee, Patrick G. Clay, W. Klugh Kennedy et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2010 · 59 citations · Full text

Pharmacy, American College, Pharmaceutical Practice +12